FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600889385> ?p ?o ?g. }

• W2600889385 endingPage "737" @default.
• W2600889385 startingPage "733" @default.
• W2600889385 abstract "Chronic myeloid leukaemia (CML) is driven by the activity of the BCR-ABL1 fusion oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with CML, with over 80% of patients treated with imatinib surviving for more than 10 years. Second-generation ABL1 kinase inhibitors induce more potent molecular responses in both previously untreated and imatinib-resistant patients with CML. Studies in patients with chronic-phase CML have shown that around 50% of patients who achieve and maintain undetectable BCR-ABL1 transcript levels for at least 2 years remain disease-free after the withdrawal of treatment. Here we characterize ABL001 (asciminib), a potent and selective allosteric ABL1 inhibitor that is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia. In contrast to catalytic-site ABL1 kinase inhibitors, ABL001 binds to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation. ABL001 and second-generation catalytic inhibitors have similar cellular potencies but distinct patterns of resistance mutations, with genetic barcoding studies revealing pre-existing clonal populations with no shared resistance between ABL001 and the catalytic inhibitor nilotinib. Consistent with this profile, acquired resistance was observed with single-agent therapy in mice; however, the combination of ABL001 and nilotinib led to complete disease control and eradicated CML xenograft tumours without recurrence after the cessation of treatment." @default.
• W2600889385 created "2017-04-07" @default.
• W2600889385 creator A5002600757 @default.
• W2600889385 creator A5003934063 @default.
• W2600889385 creator A5007968093 @default.
• W2600889385 creator A5011454613 @default.
• W2600889385 creator A5012171078 @default.
• W2600889385 creator A5023165455 @default.
• W2600889385 creator A5027110130 @default.
• W2600889385 creator A5027947663 @default.
• W2600889385 creator A5033602150 @default.
• W2600889385 creator A5039840587 @default.
• W2600889385 creator A5041829403 @default.
• W2600889385 creator A5043647084 @default.
• W2600889385 creator A5047899373 @default.
• W2600889385 creator A5054649453 @default.
• W2600889385 creator A5054650617 @default.
• W2600889385 creator A5057024955 @default.
• W2600889385 creator A5057346782 @default.
• W2600889385 creator A5063410226 @default.
• W2600889385 creator A5065795560 @default.
• W2600889385 creator A5068320814 @default.
• W2600889385 creator A5072778946 @default.
• W2600889385 creator A5075196845 @default.
• W2600889385 creator A5075522182 @default.
• W2600889385 creator A5075956429 @default.
• W2600889385 creator A5077916667 @default.
• W2600889385 creator A5080760033 @default.
• W2600889385 creator A5084059598 @default.
• W2600889385 creator A5089863595 @default.
• W2600889385 date "2017-03-01" @default.
• W2600889385 modified "2023-10-16" @default.
• W2600889385 title "The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1" @default.
• W2600889385 cites W1980590401 @default.
• W2600889385 cites W1987191607 @default.
• W2600889385 cites W1998406030 @default.
• W2600889385 cites W2010392945 @default.
• W2600889385 cites W2020103507 @default.
• W2600889385 cites W2023569481 @default.
• W2600889385 cites W2043398720 @default.
• W2600889385 cites W2050904392 @default.
• W2600889385 cites W2055603146 @default.
• W2600889385 cites W2064367288 @default.
• W2600889385 cites W2105783133 @default.
• W2600889385 cites W2106266094 @default.
• W2600889385 cites W2117356576 @default.
• W2600889385 cites W2123431502 @default.
• W2600889385 cites W2127753323 @default.
• W2600889385 cites W2150962457 @default.
• W2600889385 cites W2158933399 @default.
• W2600889385 cites W2161835431 @default.
• W2600889385 cites W2164242115 @default.
• W2600889385 cites W2432389462 @default.
• W2600889385 doi "https://doi.org/10.1038/nature21702" @default.
• W2600889385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28329763" @default.
• W2600889385 hasPublicationYear "2017" @default.
• W2600889385 type Work @default.
• W2600889385 sameAs 2600889385 @default.
• W2600889385 citedByCount "358" @default.
• W2600889385 countsByYear W26008893852017 @default.
• W2600889385 countsByYear W26008893852018 @default.
• W2600889385 countsByYear W26008893852019 @default.
• W2600889385 countsByYear W26008893852020 @default.
• W2600889385 countsByYear W26008893852021 @default.
• W2600889385 countsByYear W26008893852022 @default.
• W2600889385 countsByYear W26008893852023 @default.
• W2600889385 crossrefType "journal-article" @default.
• W2600889385 hasAuthorship W2600889385A5002600757 @default.
• W2600889385 hasAuthorship W2600889385A5003934063 @default.
• W2600889385 hasAuthorship W2600889385A5007968093 @default.
• W2600889385 hasAuthorship W2600889385A5011454613 @default.
• W2600889385 hasAuthorship W2600889385A5012171078 @default.
• W2600889385 hasAuthorship W2600889385A5023165455 @default.
• W2600889385 hasAuthorship W2600889385A5027110130 @default.
• W2600889385 hasAuthorship W2600889385A5027947663 @default.
• W2600889385 hasAuthorship W2600889385A5033602150 @default.
• W2600889385 hasAuthorship W2600889385A5039840587 @default.
• W2600889385 hasAuthorship W2600889385A5041829403 @default.
• W2600889385 hasAuthorship W2600889385A5043647084 @default.
• W2600889385 hasAuthorship W2600889385A5047899373 @default.
• W2600889385 hasAuthorship W2600889385A5054649453 @default.
• W2600889385 hasAuthorship W2600889385A5054650617 @default.
• W2600889385 hasAuthorship W2600889385A5057024955 @default.
• W2600889385 hasAuthorship W2600889385A5057346782 @default.
• W2600889385 hasAuthorship W2600889385A5063410226 @default.
• W2600889385 hasAuthorship W2600889385A5065795560 @default.
• W2600889385 hasAuthorship W2600889385A5068320814 @default.
• W2600889385 hasAuthorship W2600889385A5072778946 @default.
• W2600889385 hasAuthorship W2600889385A5075196845 @default.
• W2600889385 hasAuthorship W2600889385A5075522182 @default.
• W2600889385 hasAuthorship W2600889385A5075956429 @default.
• W2600889385 hasAuthorship W2600889385A5077916667 @default.
• W2600889385 hasAuthorship W2600889385A5080760033 @default.
• W2600889385 hasAuthorship W2600889385A5084059598 @default.
• W2600889385 hasAuthorship W2600889385A5089863595 @default.
• W2600889385 hasBestOaLocation W26008893852 @default.
• W2600889385 hasConcept C125418893 @default.
• W2600889385 hasConcept C126322002 @default.

• next